Crump Andy
Graduate School of Infection Control Sciences, Kitasato University, Minato-Ku, Japan.
J Antibiot (Tokyo). 2017 May;70(5):495-505. doi: 10.1038/ja.2017.11. Epub 2017 Feb 15.
Over the past decade, the global scientific community have begun to recognize the unmatched value of an extraordinary drug, ivermectin, that originates from a single microbe unearthed from soil in Japan. Work on ivermectin has seen its discoverer, Satoshi Ōmura, of Tokyo's prestigious Kitasato Institute, receive the 2014 Gairdner Global Health Award and the 2015 Nobel Prize in Physiology or Medicine, which he shared with a collaborating partner in the discovery and development of the drug, William Campbell of Merck & Co. Incorporated. Today, ivermectin is continuing to surprise and excite scientists, offering more and more promise to help improve global public health by treating a diverse range of diseases, with its unexpected potential as an antibacterial, antiviral and anti-cancer agent being particularly extraordinary.
在过去十年中，全球科学界开始认识到一种非凡药物——伊维菌素的独特价值，它源自从日本土壤中发现的一种单一微生物。伊维菌素的研究成果使它的发现者、东京著名的北里研究所的大村智获得了2014年盖尔德纳全球健康奖以及2015年诺贝尔生理学或医学奖，他与该药物发现和开发的合作伙伴、默克公司的威廉·坎贝尔共同获得这一奖项。如今，伊维菌素不断给科学家带来惊喜，它有望通过治疗多种疾病来改善全球公共卫生状况，其作为抗菌、抗病毒和抗癌药物的意外潜力尤为突出。
